In Brief: Boston Scientific/Scimed
This article was originally published in The Gray Sheet
Boston Scientific/Scimed: Federal Trade Commission requests additional information from the two companies regarding their proposed $865 mil. stock swap merger, which was announced in November ("The Gray Sheet" Nov. 14, 1994, p. 12). The additional information pertains to "the activities of the two companies in the area of intravascular ultrasound," the firms say in a joint statement. In September, Boston Scientific entered a definitive agreement to acquire IVUS system manufacturer Cardiovascular Imaging Systems in a deal valued at about $100 mil. Both Boston Scientific and Scimed have also been developing IVUS technology. The companies say that the FTC request is "not unusual for this type of transaction"...
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.